User menu

Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipids

Bibliographic reference Hermans, Michel ; Ahn, Sylvie A. ; Rousseau, Michel. Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipids. In: Cardiovascular Diabetology, Vol. 13, p. 56 [1-8] (2014)
Permanent URL
  1. Cohn J. S., Marcoux C., Davignon J., Detection, Quantification, and Characterization of Potentially Atherogenic Triglyceride-Rich Remnant Lipoproteins, 10.1161/01.atv.19.10.2474
  2. Brunzell J. D., Davidson M., Furberg C. D., Goldberg R. B., Howard B. V., Stein J. H., Witztum J. L., Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation, 10.2337/dc08-9018
  3. Fujioka Yoshio, Ishikawa Yuichi, Remnant Lipoproteins As Strong Key Particles to Atherogenesis, 10.5551/jat.e598
  4. Kannel William B, Vasan Ramachandran S, Triglycerides as vascular risk factors: new epidemiologic insights : , 10.1097/hco.0b013e32832c1284
  5. Jacobson Terry A., Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk, 10.4065/mcp.2011.0128
  6. Langsted A., Freiberg J. J., Tybjaerg-Hansen A., Schnohr P., Jensen G. B., Nordestgaard B. G., Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up : Cholesterol, triglycerides and myocardial infarction, 10.1111/j.1365-2796.2010.02333.x
  7. Jørgensen Anders Berg, Frikke-Schmidt Ruth, West Anders Sode, Grande Peer, Nordestgaard Børge G., Tybjærg-Hansen Anne, Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction, 10.1093/eurheartj/ehs431
  8. McPherson Ruth, Remnant Cholesterol, 10.1016/j.jacc.2012.11.009
  9. Varbo Anette, Benn Marianne, Tybjærg-Hansen Anne, Jørgensen Anders B., Frikke-Schmidt Ruth, Nordestgaard Børge G., Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease, 10.1016/j.jacc.2012.08.1026
  10. Zambon Alberto, Puato Massimo, Faggin Elisabetta, Grego Franco, Rattazzi Marcello, Pauletto Paolo, Lipoprotein remnants and dense LDL are associated with features of unstable carotid plaque: A flag for non-HDL-C, 10.1016/j.atherosclerosis.2013.06.024
  11. Fruchart Jean-Charles, Duriez Patrick, HDL and triglyceride as therapeutic targets : , 10.1097/00041433-200212000-00003
  12. Martin Seth S., Blaha Michael J., Toth Peter P., Joshi Parag H., McEvoy John W., Ahmed Haitham M., Elshazly Mohamed B., Swiger Kristopher J., Michos Erin D., Kwiterovich Peter O., Kulkarni Krishnaji R., Chimera Joseph, Cannon Christopher P., Blumenthal Roger S., Jones Steven R., Very Large Database of Lipids: Rationale and Design : Very Large Database of Lipids, 10.1002/clc.22214
  13. Martin Seth S., Blaha Michael J., Elshazly Mohamed B., Toth Peter P., Kwiterovich Peter O., Blumenthal Roger S., Jones Steven R., Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile, 10.1001/jama.2013.280532
  14. Hermans Michel P, Sacks Frank M, Ahn Sylvie A, Rousseau Michel F, Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence, 10.1186/1475-2840-10-20
  15. Bairaktari Eleni, Hatzidimou Katerina, Tzallas Christos, Vini Maria, Katsaraki Afroditi, Tselepis Alexandros, Elisaf Moses, Tsolas Orestes, Estimation of LDL cholesterol based on the Friedewald formula and on apo B levels, 10.1016/s0009-9120(00)00162-4
  16. Martin Seth S., Blaha Michael J., Elshazly Mohamed B., Brinton Eliot A., Toth Peter P., McEvoy John W., Joshi Parag H., Kulkarni Krishnaji R., Mize Patrick D., Kwiterovich Peter O., DeFilippis Andrew P., Blumenthal Roger S., Jones Steven R., Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications, 10.1016/j.jacc.2013.01.079
  17. Hermans M. P., Levy J. C., Morris R. J., Turner R. C., Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes, 10.1007/s001250051215
  18. Alberti K.G.M.M., Eckel R. H., Grundy S. M., Zimmet P. Z., Cleeman J. I., Donato K. A., Fruchart J.-C., James W. P. T., Loria C. M., Smith S. C., Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity, 10.1161/circulationaha.109.192644
  19. Levey Andrew S., A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation, 10.7326/0003-4819-130-6-199903160-00002
  20. Hermans Michel P., Ahn Sylvie A., Rousseau Michel F., The multi-faceted outcomes of conjunct diabetes and cardiovascular familial history in type 2 diabetes, 10.1016/j.jdiacomp.2012.03.014
  21. Kothari V., Stevens R. J., Adler A. I., Stratton I. M., Manley S. E., Neil H. A., Holman R. R., UKPDS 60: Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine, 10.1161/01.str.0000020091.07144.c7
  22. Hermans Michel P, Ahn Sylvie A, Rousseau Michel F, log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males, 10.1186/1475-2840-9-88
  23. Hermans Michel P, Ahn Sylvie A, Rousseau Michel F, The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females, 10.1186/1476-511x-11-132
  24. Querton Laurent, Buysschaert Martin, Hermans Michel P., Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels, 10.1016/j.jacl.2012.04.002
  25. Murase Toshio, Okubo Minoru, Takeuchi Ichiro, Non-HDL-cholesterol/apolipoprotein B ratio: A useful distinguishing feature in the screening for type III hyperlipoproteinemia, 10.1016/j.jacl.2010.01.004
  26. Bestehorn Kurt, Smolka Wenefrieda, Pittrow David, Schulte Helmut, Assmann Gerd, Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care, 10.1185/03007995.2010.532088
  27. Fruchart J.C., Sacks F.M., Hermans M.P., , Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction Initiative (R3i), 10.1185/03007995.2010.489341
  28. Reyes-Soffer G., Ngai C. I., Lovato L., Karmally W., Ramakrishnan R., Holleran S., Ginsberg H. N., Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial, 10.2337/dc11-2556
  29. Tenenbaum Alexander, Fisman Enrique Z, Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction, 10.1186/1475-2840-11-125
  30. Fruchart Jean-Charles, Davignon Jean, Hermans Michel P, Al-Rubeaan Khalid, Amarenco Pierre, Assmann Gerd, Barter Philip, Betteridge John, Bruckert Eric, Cuevas Ada, Farnier Michel, Ferrannini Ele, Fioretto Paola, Genest Jacques, Ginsberg Henry N, Gotto Antonio M, Hu Dayi, Kadowaki Takashi, Kodama Tatsuhiko, Krempf Michel, Matsuzawa Yuji, Núñez-Cortés Jesús, Monfil Carlos, Ogawa Hisao, Plutzky Jorge, Rader Daniel J, Sadikot Shaukat, Santos Raul D, Shlyakhto Evgeny, Sritara Piyamitr, Sy Rody, Tall Alan, Tan Chee, Tokgözoğlu Lale, Toth Peter P, Valensi Paul, Wanner Christoph, Zambon Alberto, Zhu Junren, Zimmet Paul, , Residual macrovascular risk in 2013: what have we learned?, 10.1186/1475-2840-13-26